Selected clinical trials combining immunostimulatory agents with rituximab for patients with indolent non-Hodgkin lymphoma (NHL).
| Reference . | Agent . | Suggested Activity . | N . | Major Findings . |
|---|---|---|---|---|
| Abbreviations: IL, interleukin; GCSF, granulocyte colony-stimulating factor; IFN, interferon; ADCC, antibody-mediated cellular cytotoxicity; NK, natural killer; ORR, overall response rate; CR, complete response; CpG, Immunostimulatory oligonucleotides | ||||
| Friedberg34 | IL-2 | Enhance ADCC: NK | 20 | ORR 55%; prolonged response duration |
| Gluck35 | IL-2 | Enhance ADCC: NK | 34 | ADCC activity correlated with response |
| Ansell32 | IL-12 | Enhance ADCC: NK | 43 | ORR 69%; High CR rate |
| van der Kolk33 | GCSF | Enhance ADCC: neutrophil | 26 | ORR 42%; prolonged response duration |
| Davis31 | IFN-α | Enhance ADCC: NK; CD20 | 38 | ORR 45%; prolonged response duration |
| Sacci40 | IFN-α | Enhance ADCC: NK; CD20 | 64 | ORR 70%; prolonged response duration |
| Friedberg39 | CpG | Microenvironment | 20 | ORR 32%; Type 1 IFN induction |
| Reference . | Agent . | Suggested Activity . | N . | Major Findings . |
|---|---|---|---|---|
| Abbreviations: IL, interleukin; GCSF, granulocyte colony-stimulating factor; IFN, interferon; ADCC, antibody-mediated cellular cytotoxicity; NK, natural killer; ORR, overall response rate; CR, complete response; CpG, Immunostimulatory oligonucleotides | ||||
| Friedberg34 | IL-2 | Enhance ADCC: NK | 20 | ORR 55%; prolonged response duration |
| Gluck35 | IL-2 | Enhance ADCC: NK | 34 | ADCC activity correlated with response |
| Ansell32 | IL-12 | Enhance ADCC: NK | 43 | ORR 69%; High CR rate |
| van der Kolk33 | GCSF | Enhance ADCC: neutrophil | 26 | ORR 42%; prolonged response duration |
| Davis31 | IFN-α | Enhance ADCC: NK; CD20 | 38 | ORR 45%; prolonged response duration |
| Sacci40 | IFN-α | Enhance ADCC: NK; CD20 | 64 | ORR 70%; prolonged response duration |
| Friedberg39 | CpG | Microenvironment | 20 | ORR 32%; Type 1 IFN induction |